Michael Halpin
Chief Operating Officer chez VERICEL CORPORATION
Fortune : 49 367 $ au 31/03/2024
Postes actifs de Michael Halpin
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| VERICEL CORPORATION | Chief Operating Officer | 15/06/2019 | - |
| General Counsel | 10/04/2017 | 15/06/2019 |
Historique de carrière de Michael Halpin
Anciens postes connus de Michael Halpin
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | General Counsel | 01/02/2002 | - |
| Corporate Officer/Principal | - | 01/04/2017 | |
| Sanofi Corp. | Corporate Officer/Principal | - | - |
Formation de Michael Halpin
| University of Virginia | Graduate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
Opérationnelle
| General Counsel | 2 |
| Corporate Officer/Principal | 2 |
| Chief Operating Officer | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| VERICEL CORPORATION | Health Technology |
| Entreprise privées | 2 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
| Sanofi Corp. |
- Bourse
- Insiders
- Michael Halpin
- Expérience
